Edition:
United States

Evofem Biosciences Inc (EVFM.OQ)

EVFM.OQ on NASDAQ Stock Exchange Capital Market

3.50USD
16 Nov 2018
Change (% chg)

$0.13 (+3.86%)
Prev Close
$3.37
Open
$3.50
Day's High
$3.53
Day's Low
$3.47
Volume
5,624
Avg. Vol
16,672
52-wk High
$12.84
52-wk Low
$1.80

Latest Key Developments (Source: Significant Developments)

Evofem Biosciences Q3 Loss Per Share $0.71
Wednesday, 7 Nov 2018 06:50am EST 

Nov 7 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.71.Q3 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S.EVOFEM BIOSCIENCES- EXPECTS QUARTERLY CASH BURN TO DECREASE TO APPROXIMATELY $7 TO 9 MILLION DURING Q4 OF 2018.  Full Article

Evofem Biosciences Inc Files For Secondary Offering Of Up To 17 Million Shares - SEC Filing
Friday, 16 Mar 2018 04:40pm EDT 

March 16 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES INC FILES FOR SECONDARY OFFERING OF UP TO 17 MILLION SHARES - SEC FILING.  Full Article

Neothetics to pay $1.5 mln‍​‍​ to Evofem Biosciences if deal terminated
Tuesday, 17 Oct 2017 08:33am EDT 

Oct 17 (Reuters) - Neothetics Inc :Neothetics says if merger agreement with Evofem Biosciences terminated under specified circumstances, co to pay Evofem termination fee of up to $1.5 mln‍​‍​.  Full Article

Neothetics Inc and Evofem Biosciences Inc announce merger agreement to create Women’S health company
Tuesday, 17 Oct 2017 08:00am EDT 

Oct 17 (Reuters) - Neothetics Inc :Neothetics Inc and Evofem Biosciences, Inc. announce merger agreement to create Women’S health company.Neothetics Inc - ‍privately-held Evofem Biosciences will merge with a wholly-owned subsidiary of Neothetics in an all-stock transaction​.Neothetics - ‍Invesco Asset Management entered securities purchase agreement to acquire additional $20 million of common stock in combined Co​.Neothetics Inc - ‍transactions have been approved by board of directors of both companies​.Neothetics - Neothetics will be renamed Evofem Biosciences and will be under leadership of Evofem Biosciences' CEO Saundra Pelletier​.Neothetics Inc - merger ‍exchange ratio assumes $171.4 million in value of Co's common stock will be issued to Evofem Biosciences stockholders in merger​.Neothetics - current Neothetics stockholders to own about 13% of combined company & current Evofem stockholders to own about 87% of combined company​.Neothetics Inc - ‍merger exchange ratio assumes $28.6 million in value of common stock being retained by Neothetics stockholders​.Neothetics Inc - ‍following merger, company will be led by Saundra Pelletier as chief executive officer​.  Full Article

Neothetics posts Q2 loss per share $0.20
Thursday, 10 Aug 2017 08:00am EDT 

Aug 10 (Reuters) - Neothetics Inc :Neothetics provides business update and reports second quarter 2017 financial results.Q2 loss per share $0.20.Neothetics Inc - research and development expenses for Q2 of 2017 were approximately $1.6 million, compared to $1.4 million for same quarter in 2016.  Full Article

Neothetics reduces full-time workforce
Wednesday, 12 Jul 2017 06:24am EDT 

July 12 (Reuters) - Neothetics Inc ::Neothetics Inc says it has implemented reduction of co's current full-time workforce of 6 employees to 2 employees.Neothetics Inc says reduction of workforce in order to reduce operating expenses and conserve cash resources.Neothetics Inc estimates that it will incur aggregate cash charges of approximately $385,000 associated with workforce reduction during 2017.Says expects that this workforce reduction will be effectuated during Q3 of 2017.Neothetics - reduction of workforce in light of co's lipo-202 trial results announced last month.  Full Article

Neothetics announces review of strategic alternatives
Monday, 10 Jul 2017 05:45pm EDT 

July 10 (Reuters) - Neothetics Inc :Neothetics announces review of strategic alternatives.Neothetics Inc - ‍Intends to streamline its operations in order to preserve its capital and cash resources, including implementing a reduction in workforce​.Neothetics Inc - ‍Neothetics has engaged Oppenheimer and Co., Inc. to act as its exclusive financial advisor to company and board for this process​.Neothetics Inc - Has unanimously approved plans to initiate a process to explore and review a range of strategic alternatives.Says "continue to review all operational expenses in order to facilitate our ability to enter into a strategic transaction".Neothetics - ‍Initiate process to explore and review range of strategic alternatives focusing on seeking acquisition, business combination or partnership​.  Full Article

Neothetics reports Q1 loss per share $0.22
Thursday, 11 May 2017 08:00am EDT 

May 11 (Reuters) - Neothetics Inc -:Neothetics provides business update and reports first quarter 2017 financial results.Q1 loss per share $0.22.Neothetics Inc - cash and cash equivalents were $9.7 million as of march 31, 2017 compared to $11.5 million as of december 31, 2016.  Full Article

Neothetics reports Q4 loss per share of $0.14
Thursday, 23 Mar 2017 08:00am EDT 

Neothetics Inc : Neothetics provides business update and reports fourth quarter 2016 financial results .Q4 loss per share $0.14.  Full Article

Neothetics reports last subject enrolled in phase 2 proof of concept trial for lipo-202
Monday, 20 Mar 2017 08:00am EDT 

Neothetics Inc : Neothetics announces last subject enrolled in phase 2 proof of concept trial for lipo-202 for the reduction of submental subcutaneous fat .Expects to report top-line data in June 2017.  Full Article